版本:
中国

BRIEF-Ipsen and Exelixis announce positive results from Phase 2 CABOSUN trial of cabozantinib

Oct 10 Ipsen SA :

* Ipsen and its partner Exelixis announce positive results from Phase 2 CABOSUN Trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

* Cabozantinib met primary endpoint of improving progression-free survival as compared to sunitinib, decreasing rate of disease progression or death by 31 percent

* Objective response rate significantly improved: 46 percent for cabozantinib versus 18 percent for sunitinib Source text for Eikon: Further company coverage: (Gdynia Newsroom)

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐